ASSESSMENT OF THE EFFICACY OF ADALIMUMAB TREATMENT IN HIDRADENITIS SUPPURATIVA: A SINGLE-CENTER STUDY

Yıl 2023, Cilt: 32 Sayı: 3, 399 - 402, 04.12.2023

Eda Öksüm Solak

https://doi.org/10.34108/eujhs.1306589

Öz

Hidradenitis suppurativa (HS), is a chronic disease characterized by recurrent subcutaneous nodules, abscesses, and draining sinuses. Adalimumab is used for moderate to severe HS cases that do not respond to systemic treatments. The aim of our study was to evaluate the efficacy of adalimumab treatment in patients with HS who received treatment at our clinic. The medical records of patients aged 18 years and older who received adalimumab treatment for HS between 2016 and 2021 were retrospectively reviewed. When patients were evaluated in terms of Hidradenitis Suppurativa Clinical Response (HISCR) at the end of 3 months, 6 (31.6%) patients had achieved HISCR within 3 months. After 6 months of treatment, an additional 9 (47.4%) patients had reached the HISCR endpoint. At the end of 6 months, no response was observed in 4 patients (21.1%). Based on the data obtained from the study, adalimumab is considered to be an effective and safe treatment method for moderate to severe HS patients.

Anahtar Kelimeler

Adalimumab, Hidradenitis Suppurativa, Therapy, Drug, Efficiency

HİDRADENİTİS SÜPÜRATİVADA ADALİMUMAB TEDAVİSİNİN ETKİNLİĞİNİN DEĞERLENDİRİLMESİ: TEK MERKEZLİ BİR ÇALIŞMA

Öz

Hidradenitis süpürativa (HS), deri altında nodüller, apseler ve drene olan sinüslerin görülebildiği tekrarlayıcı bir hastalıktır. Adalimumab, sistemik tedavilere yanıt vermeyen orta ila şiddetli HS için kullanılmaktadır. Çalışmamızda kliniğimizde adalimumab tedavisi alan HS hastalarında etkinliği değerlendirmeyi amaçladık. Çalışmaya kliniğimize 2016-2021 yılları arasında başvuran, 18 yaşından büyük HS nedeniyle adalimumab tedavisi alan hastaların dosyaları retrospektif olarak taranmıştır. Hastalar 3 ay sonunda Hidradenitis Suppurativa Clinical Response (HiSCR) ile değerlendirildiğinde 6 (%31.6) hasta HiSCR’ye ulaşmıştı. Altı aylık tedavi sonrasında 9 (%47.4) hasta daha HiSCR değerine ulaşmıştı. Altı ayın sonunda 4 hastada (%21.1) tedaviye herhangi bir yanıt elde edilmedi.Çalışmadan elde edilen veriler neticesinde orta-şiddetli HS hastalarında adalimumabın etkili ve güvenli bir tedavi yöntemi olduğu düşünülmüştür.

Anahtar Kelimeler

Adalimumab, Hidradenitis Süpürativa, Tedavi, İlaç, Etkinlik

Kaynakça

• Kouris A, Platsidaki E, Christodoulou C, et al. Quality of Life and Psychosocial Implications in Patients with Hidradenitis Suppurativa. Dermatology 2016;232:687-691.
• Kim ES, Garnock-Jones KP, Keam SJ. Adalimumab: A Review in Hidradenitis Suppurativa. Am J Clin Dermatol 2016;17:545-552.
• Garg A, Lavian J, Lin G, Strunk A, Alloo A. Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis. J Am Acad Dermatol 2017; 77:118-122.
• Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2020;82:1045-1058.
• Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol 2014; 71:1144-1150.
• Sabat R, Jemec GBE, Matusiak Ł, et al. Hidradenitis suppurativa. Nat Rev Dis Primers 2020; 6:18.
• Ingram JR, Collier F, Brown D,et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol 2019; 180:1009-1017.
• Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: A practical framework for treatment optimization—Systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol 2019; 33:19-31.
• Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A comparison of international management guidelines for hidradenitis suppurativa. Dermatology 2021; 237:81-96.
• Magalhaes RF, Rivitti-Machado MC, Duarte GV, et al. Consensus on the treatment of hidradenitis suppurativa—Brazilian Society of Dermatology. An Bras Dermatol 2019; 94:7-19.
• Dastoli S, Nistico SP, Morrone P, et al. Colchicine in Managing Skin Conditions: A Systematic Review. Pharmaceutics 2022; 14:294.
• Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J EurAcad Dermatol Venereol 2015; 29(4):619-644.
• Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J EurAcad Dermatol Venereol 2021; 35(1):50-61.
• Choi E, Chandran NS. Rethinking the female predominance in hidradenitis suppurativa. Int J Dermatol 2019; 58:e57-58.
• Schrader AM, Deckers IE, van der Zee HH, Boer J, Prens EP. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol 2014; 71:460-467.
• Lee JW, Heo YW, Lee JH, Lee S. Epidemiology and comorbidity of hidradenitis suppurativa in Korea for 17 years: A nationwide population-based cohort study. J Dermatol 2023 Feb 20.
• Ozkur E, Karadag AS, Ustuner P, et al. Clinical and Demographic Features of Hidradenitis Suppurativa: A Multicentre Study of 1221 Patients with an Analysis of Risk Factors Associated with Disease Severity. Clin ExpDermatol 2021; 46:532-540.
• Zimman S, Comparatore MV, Vulcano AF, Absi ML, Mazzuoccolo LD. Hidradenitis Suppurativa: Estimated Prevalence, Clinical Features, Concomitant Conditions, and Diagnostic Delay in a University Teaching Hospital in Buenos Aires, Argentina. Actas Dermosifiliogr (Engl Ed) 2019;110:297-302.
• Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitissuppurativa: a parallel randomized trial. Ann Intern Med 2012; 157:846-855.
• Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol 2011; 165:391-398.
• Chiricozzi A, Giovanardi G, Garcovich S, et al. Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience. Acta DermVenereol 2020; 100:5775.
• Hafner A, Ghislain PD, Kovács R, et al. Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study. J Eur Acad Dermatol Venereol. 2021; 35:2277-2284.
• Hayashi N, Hayama K, Takahashi K, et al. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan. J Dermatol 2022; 49:411-421.
• Aparício Martins I, Valente C, Simões Farinha P, Figueira Vilela B, Cabete J. Passive smoking and hidradenitis suppurativa: a retrospective analysis. J EurAcad Dermatol Venereol 2023; 37:e466-e467.
• Kromann CB, Deckers IE, Esmann S, et al.Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol 2014; 171:819-824.
• Denny G, Anadkat MJ. The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: an institutional retrospective cohort study. J Am Acad Dermatol 2017; 76:54-59.